Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GOP Moves to Repeal Medical Device Tax - Medical Product Outsourcing
OEM News

GOP Moves to Repeal Medical Device Tax

GOP Moves to Repeal Medical Device Tax

GOP Moves to Repeal Medical Device Tax

 

Lawmakers on Capitol Hill are playing politics with the medical device industry—this time in a move most in the industry would applaud. On Jan. 26, companion bills were introduced in the U.S. House of Representatives and the Senate to repeal the medical device tax included in the Patient Protection and Affordable Care Act—commonly called the healthcare reform law—passed last year.


Rep. Erik Paulsen (R-Minn.), who proposed a similar measure last year, introduced the Protect Medical Innovation Act in the House. Sen. Orrin Hatch (R-Utah), introduced the Senate bill. The legislation would repeal the 2.3 percent excise tax on medical device sales, which originally was included in the healthcare legislation as a way to help pay for healthcare reform.


Slated to take effect in 2013, the tax is estimated to raise $20 billion in 10 years. Industry legislators and lobbyists for the medical technology industry were successful last year in cutting the original $40 billion tax proposal in half. The tax would equate to a roughly 3.5 percent tax levied on the total revenues of a company. If the healthcare reform law had been in effect last year, the 10 largest medical device makers would have generated 86 percent of the $1.87 billion in excise taxes last year.


“Taxing the medical technology industry to the tune of $20 billion will only stifle growth, innovation, and access to the life-saving technologies U.S. device companies produce,” Paulsen, who co-chairs the House Medical Technology Caucus, said in a statement. Hatch, who serves as the ranking member of the Senate Finance Committee, said the tax would “cripple an important engine of opportunity, job growth and innovation, while hurting the advancement of technologies essential to improving patient care.”


The Washington, D.C.-based Medical Device Manufacturers Association (MDMA), one of the medical device industry’s chief advocacy groups, was quick to support

the move.


“The United States is the global leader in medical technology and innovation, and the repeal of such an onerous tax will help us maintain our position,” said Mark B. Leahey, MDMA’s president and CEO. “It is crucial that we support entrepreneurs and engineers who continue to create quality jobs and physicians who focus on improving the quality of life for patients, especially in an increasingly competitive global marketplace. “When our nation’s job-creators face a future with additional taxes and an unpredictable regulatory environment, growth and innovation are stifled. Instead, we need policies that provide incentives for hiring employees and investments in research and innovation.”


Leahey also said the tax would “disproportionately harm small businesses that develop the majority of innovative andcutting-edge technologies.”


Many medical device industry leaders have said the tax would send more of the industry’s manufacturing jobs offshore and curtail research and development.


FDA Calls for Stricter Defibrillator Testing


The U.S. Food and Drug Administration (FDA) has recommended stricter safety measures for cardiovascular defibrillators after years of increasing problems with the emergency medical devices. The tighter regulation is intended to bring design and manufacturing flaws with the devices under control. Though not required to follow its advice, the FDA will ask an expert panel to evaluate the recommendations.


Defibrillators use electric shocks to jolt the heart back to normal after patients collapse from cardiac arrest. The new guidelines would not apply to implantable cardioverter defibrillators, which are surgically inserted into patients with heart problems.


Manufacturers of external defibrillators would have to submit more data and undergo manufacturing inspections before launching a new product. External defibrillators can be purchased for the home and often can be found throughout airports, shopping malls, sporting arenas, office buildings and other larger areas where numbers of people gather.


External defibrillators usually include two plastic pads that attach to the patient’s chest and detect whether the heart is suffering an abnormal heart rhythm. If the problem can be corrected, which is the case about one-fourth of the time, the pads deliver an electric shock that resets the heart’s pumping action. Nearly 300,000 people in the U.S. collapse each year from cardiac arrest, according to the FDA. Academics estimate nearly 500 lives are saved each year in the U.S. as a result of bystanders using the devices.


Medical device manufacturers have issued 68 recalls of defibrillators in the last five years, according to the FDA, and the agency has received more than 23,000 reports of device malfunctions, “including some where the device failure occurred during a rescue attempt and may have contributed to patient harm or death.”


Currently, makers of defibrillators are approved through the 510(k) system, which traditionally has allowed for a quicker time to market because approval is based on devices that are similar to products already on the market. Regulators only inspect the companies’ manufacturing facilities if they have cause to suspect a problem. Companies including Philips Healthcare, Cardiac Science Corp., Defibtech and others have petitioned the FDA to keep their devices approved at this standard. The FDA maintains that stricter measures are needed because defibrillator makers have failed to fix problems that have led to the recall of hundreds of thousands of devices.


Under the FDA’s proposal, device manufacturers would be subject to regular inspections and could be required to submit additional clinical data before launching a new version of their defibrillator. This is the current standard for implantable defibrillators, heart valves and other devices that help keep patients alive.


Guidant Fined, Given Probation for Defective Heart Devices


A federal judge fined Guidant LLC $296 million and ordered the troubled division of Boston Scientific Corp. to serve three years of probation for withholding information from doctors and patients about a safety problem with some implantable heart devices.


The sentence imposed by U.S. District Judge Donovan Frank in Minnesota on Jan. 12 requires Guidant to pay a fine of nearly $254 million, a figure based on the company’s pre-tax profit on sales of the defective devices as well as its “culpability” in the criminal case. Guidant also forfeits about $42 million to the federal government for selling the heart devices without first reporting the problems to regulators as required by law. Frank said the sentence “provides a deterrent effect, and most importantly, provides respect for the law.”


Guidant pleaded guilty nine months ago to two misdemeanor counts, but Frank rejected the deal, preferring instead to subject the firm to probation, community service and better scrutiny of the company’s ongoing compliance with federal law. Though the sentence includes probation, Frank said he’d be willing to reduce the length of the supervision if the company complies with federal law. Boston Scientific plans to ensure its division doesn’t stray—it has committed $15 million during the next three years to expanding two existing community programs.


Guidant attorney Daniel Scott said in court documents that the company had improved its compliance policies since 2005 and upgraded them further after it was acquired by Boston Scientific in 2006.“The company has learned a lot from this. It has learned a lot from its mistakes,” Scott told the judge. “We think, Your Honor, that we’re not what we were five years ago. We are much better.”


To show the court just how much better it has become, Guidant agreed to Frank’s demand that it make its quarterly reports available to probation officials and be subject to unannounced inspections. Federal prosecutors seemed pleased: “We think justice has been served,” Assistant U.S. Attorney Robert Lewis told the St. PaulPioneer Press.


Lewis might be in the minority, though. Randy Hopper, an attorney representing victims involved in the Guidant litigation, called the final sentence a disappointment because of the improbability that the forfeited money will be given to patients. The lawsuit Hopper initiated on behalf of victims culminated in 2007 with Boston Scientific agreeing to pay up to $240 million to settle 8,550 claims.


“The company is pleased that this issue is now resolved,” read a statement released by Boston Scientific on Jan. 12. “We continue to believe that Guidant and its employees acted in good faith and with the intention of complying with applicable laws and regulations.”


Frank’s sentencing culminates five years worth of investigations into the 2005 recalls of three types of implantable cardiac defibrillators (ICDs). The devices shock failing hearts back into rhythm and are a top source of revenue for Natick, Mass.-based Boston Scientific, Minneapolis, Minn.-based Medtronic Inc., and St. Paul, Minn.-based St. Jude Medical Inc.


Guidant sold the defective ICDs under the brand names Ventak Prizm 2 DR, Contak Renewal and Contak Renewal 2. Lewis said in court that Guidant executives deliberately hid information from regulators, claiming in legal filings that the company admitted to problems with the heart devices only after two Minnesota doctors told The New York Times about its failure to reveal the product defects. The doctors were investigating the death of 21-year-old Joshua Oukrop of Grand Rapids, Mich., whose defibrillator short-circuited while mountain biking in March 2005.


Prosecutors claim the defibrillator’s defects have caused the deaths of at least 13 people, including one just last year.


After Oukrop’s death, the doctors sought more information from Guidant and learned the company had been aware of 25 other cases in which Prizm devices had short-circuited, according to prosecutors. The problem had not been broadly disclosed outside the company and Guidant rejected the doctors’ call for apublic warning.


“Dr. [Barry] Maron’s response was to tell the Guidant officials that not communicating what they knew would be ‘the biggest mistake they would ever make,’ “ prosecutors wrote in a court filing this month. “Guidant’s retort to Dr. Maron was simply, ‘We don’t agree.’ “


The Prizm devices were prone to an electrical arcing problem that would render them inoperative and unable to delivery therapy, prosecutors said. The company made changes to the design of the devices to deal with the issue in 2002, but failed to explain the matter to regulators in a full or timely fashion, prosecutors charged.


The Renewal devices suffered from a similar problem that the company also was dangerously slow to acknowledge, according to prosecutors. The company had determined by July 2004 that the product’s labeling was false and misleading with regard to the issue, prosecutors alleged, and the problem was serious enough that it stopped production and shipment of new Renewal devices.


Yet, Guidant “explicitly directed that any defective devices that had already left the factory continue to be implanted in patients,” prosecutors wrote in their filing.


“In all, 163 defective Renewals were implanted in the United States after Guidant ordered its factory to halt production,” prosecutors wrote. “Roughly 200 more were implanted outside the United States during this period.”


Stryker’s Bone Growth Division Sold to Olympus Corp.


Stryker Corp. has inked a deal to sell its bone growth product franchise—the OP-1 product line—to the Olympus Corporation for $60 million. The product line was manufactured by Stryker’s Hopkinton, Mass.-based subsidiary Stryker Biotech LLC. The deal also includes the divestiture of the Kalamazoo, Mich.-based orthopedic giant’s manufacturing plant in Lebanon, N.H. The transaction has been cleared by the boards of both companies.


The OP-1 product line includes OP-1 Implant and OP-1 Putty for use in orthopedic bone applications such as lumbar spine fusion and the treatment of long bone fractures. The active ingredient in these products is the OP-1 bone growth factor that induces the formation of new bone when implanted.


OP-1 products currently are approved in the United States by the U.S. Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE), having provided treatment to roughly 40,000 patients globally. The HDE allows a medical device to be marketed whose effectiveness has not been fully proven and is intended to benefit patients with a rare disease or condition that afflict fewer than 4,000 U.S. patients annually.


In August, the company settled a lawsuit filed against its biotech division by the Massachusetts attorney general accusing it of illegally promoting the combination of a pair of its OP-1 products not approved by the FDA. Stryker paid $1.35 million to settle the suit.

With the sale of OP-1, Stryker officials said they plan to redirect a part of the related R&D spending to other internal projects, which they believe have the potential to deliver better returns.


Boston Sci Closes Division Sale to Stryker Corp.


On Jan. 3, Boston Scientific Corp. completed the previously announced sale of its neurovascular business to Stryker Corp. In addition, the company also prepaid $600 million in senior notes that were due on June 1. There will be a pretax charge of $15 million in the fourth quarter for accelerated interest expense on the prepayment,officials said.


The neurovascular business is based in Fremont, Calif., and makes devices that are used to treat brain aneurysms and other vascular diseases that affect the brain. Its products include stents and detachable coils. Stryker and Boston Scientific announced the deal in late November.


Boston Scientific said Stryker paid $1.38 billion upfront for the business, along with a $50 million milestone payment. Another $24 million was placed in escrow and will be released when the deal closes in foreign markets. Stryker will pay the last $50 million when some manufacturing facilities are transferred or separated from Boston Scientific. The Natick, Mass.-based device firm has begun to reshape its product offering in the face of slower sales for itsprimary heart stents and implantable defibrillators businesses. Kalamazoo, Mich.-based Stryker also is looking into faster-growth opportunities after sales of its hip and knee replacement joints slowed in the recession.


The company is focused on paying down a large debt load it accumulated in the 2006 acquisition of Guidant Corp. It also plans to record a pretax gain from the sale of the neurovascular business of more than $500 million in the first quarter. Profit for 2011 would be reduced by about 4 to 6 cents, according to Boston Scientific. Stryker said the deal will be neutral to its profit in 2011 or could increase it slightly. That estimate excludes one-time charges.


Report Says U.S. and European Device Recalls About the Same


Medical device recalls occur at comparable rates in Europe and the United States, despite a typically lengthier review process by the U.S. Food and Drug Administration (FDA), according to a report released by the Washington, D.C.-based Advanced Medical Technology Association (AdvaMed). The report found that the rate of severe recalls of medical devices in Europe was on par with equivalent Class I device recalls in the United States, with an average of 21 yearly recalls between 2005 and 2009 for each. Both the European Union and the United States experienced dramatic increases in the number of severe recalls in 2009.


Cardiovascular devices had the highest recall rates, followed by general hospital recalls, orthopedics and anesthesiology. Manufacturing and design issues grossly outnumbered all other sources of Class I recalls, the report noted.


“It’s well-documented that it takes longer to bring medical technology to market in the U.S. than it does in Europe. Today’s report suggests that the delay denies patients access to the most up-to-date treatments and cures without a corresponding increase in safety,” said Stephen J. Ubl, president and CEO of AdvaMed. The report was prepared for AdvaMed by the Boston Consulting Group.


Report Indicates Device Tax Could Increase Outsourcing


The tax imposed on device manufacturers as part of last year’s controversial healthcare reform legislation may be one of many factors driving the outsourcing of medical devices, according to a new report by Kalorama Information titled “Contract Manufacturing in Medical Devices.”


The healthcare market research publisher reports that the once conservative medical device industry is outsourcing at an increasing rate, and the new tax, which could put pressure on margins, will be one more factor in growing the $60 billion market for outsourcing medical devices and device parts.In order to partially subsidize healthcare financing and reduce the deficit strain, the Patient Protection and Affordable Care Act instituted a 2.3 percent excise tax on “taxable medical device” sales beginning in January 2013. Two measures recently were introduced in the House and Senate to repeal the tax.


Industry lobbying groups such as the Medical Device Manufacturers Association and the Advanced Medical Technology Association along with other groups successfully fought to reduce the target size of the tax last year (from $40 billion over ten years to $20 billion), but even in its revised form Kalorama researchers predict there will be an impact.


“The tax itself won’t force a firm to outsource,” said Bruce Carlson, publisher of Kalorama Information. “But since the law taxes revenues notwithstanding the cost of manufacture—it could add further pressure to bring costs down in order to restore profits.” Although the tax will not be a reality for device manufacturing until 2013, it is a consideration now for many in the industry, and will be for the next few years as they await any further action on healthcare reform. Because the excise tax does not include a blanket exemption for Class I devices, the large category of non-retail Class I products, a wide range of medical devices, including low-risk hospital and physician office supplies, will be subject to the new tax.


“2013 is not that far away in terms of planning for manufacturing and soliciting vendors,” Carlson said. “Device manufacturers will make outsourcing decisions in the coming year, and the future tax will be a factor on their minds.”


More information on the report can be found at: http://www.kaloramainformation.com/redirect.asp?progid=80943&productid=6059484.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters